PROSTATE-SPECIFIC ANTIGEN CHANGES BEFORE AND AFTER ADMINISTRATION OF AN ANGIOGENESIS INHIBITOR (TNP-470)

A 61-year-old man with progressive prostate cancer after initial hormo nal therapy was treated with TNP-470, an experimental agent with poten t antiangiogenesis properties. During the period of TNP-470 treatment, the concentration of serum prostate-specific antigen (PSA) rapidly in creased from 28.4 to 89.9 ng/ml. After termination of TNP-470 therapy, the concentration of PSA decreased from 89.9 to 10.3 ng/ml. This patt ern of PSA change was previously unanticipated and may eventually prov ide additional insight into the pharmacological actions of TNP-470.